Geron Announces New Data To Be Presented Highlighting The Potential Of RYTELO In Myeloid Hematologic Malignancies At Upcoming ASH Annual Meeting
Geron Announces New Data To Be Presented Highlighting The Potential Of RYTELO In Myeloid Hematologic Malignancies At Upcoming ASH Annual Meeting
傑龍宣佈將在即將舉行的ASH年度會議上發佈新數據，重點展示RYTELO在骨髓血液惡性腫瘤中的潛力。
- New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy
- Early safety results from the dose escalation phase of the Phase 1 IMproveMF study suggest potential for the tolerability of combination therapy with imetelstat and ruxolitinib in a frontline myelofibrosis patient population
- IMerge 臨床試驗的新分析表明，無論之前的治療如何，imetelstat 在低風險MDS並有輸血依賴性貧血的患者中均展現出臨床活性。
- IMproveMF 試驗第1階段劑量遞增階段的早期安全性結果顯示，用imetelstat和ruxolitinib聯合治療在一線骨髓纖維化患者群體中具有良好的耐受性潛力。
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the publication of abstracts containing new data highlighting the potential of RYTELO (imetelstat), a first-in-class telomerase inhibitor, in myeloid hematologic malignancies. Six abstracts have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting taking place from December 7-10, 2024, in San Diego, California and virtually.
傑龍公司（納斯達克: GERN）是一傢俱有商業化階段的生物製藥公司，旨在通過改變血液癌症病程來改變人們的生活。今天宣佈了摘要的出版，其中包含了展示嗜中性粒細胞的潛力的新數據，RYTELO（imetelstat）是首創的端粒酶抑制劑，在骨髓造血惡性腫瘤中具有潛力。六份摘要已被接受，將在2024年12月7日至10日於加利福尼亞州聖迭戈市舉行的第66屆美國血液學會（ASH）年會上展示，同時也將以虛擬形式呈現。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間